Cloning and Mutagenesis Market Analysis

Cloning and Mutagenesis Market Analysis

To get key market trends

  Download Free Sample

By product, the cloning and mutagenesis market is classified into cloning kits, mutagenesis kits, and other products. The cloning kits segment dominated the 53% of the market share in 2022. Cloning kits find a wide range of applications in gene cloning, protein expression, genetic engineering, and DNA sequencing among others. In biopharmaceutical industry, these kits are widely used to produce human proteins with biomedical applications. Additionally, in gene analysis, cloning kits are used for research to build recombinant and artificial versions of genes that help biologists to understand the functioning of normal gene in an organism.
 

Based on technology, the cloning and mutagenesis market is segmented into TOPO PCR cloning, blunt end cloning, seamless cloning, site-directed mutagenesis, and other technologies. The TOPO PCR cloning segment accounted for USD 832.6 million in 2022. TOPO PCR cloning technology offers several benefits that have contributed to its widespread use in molecular biology research. This technology provides a rapid and efficient method for cloning PCR products. It is convenient to use and is compatible with a wide range of PCR products, including blunt-ended, A-tailed, and phosphorylated PCR products. Additionally, TOPO cloning allows for seamless cloning without the need for DNA ligase or restriction enzymes. All these advantages of TOPO PCR technology aids in its high adoption, thereby facilitating segmental growth.
 

By end-use, the cloning and mutagenesis market is segmented into biotechnology & pharmaceutical companies, contract research organization (CROs) & CDMOs, and academic & research institutes. The biotechnology and pharmaceutical companies set to reach USD 6.4 billion by 2032. Biotechnology and pharmaceutical companies focus on drug discovery and development of novel therapies. Cloning and mutagenesis techniques play an important role in drug development by facilitating the production of therapeutic proteins and generating novel drug candidates. Moreover, these techniques can significantly impact human therapeutics by providing new cells for tissue engineering and transplantation. Such broad applications of cloning and mutagenesis in the biotechnology and pharmaceutical industry drives the segment growth.
 

North America captured around 38.6% of the cloning and mutagenesis market share in 2022. High market share can be attributed to the presence of key market players that has resulted in higher penetration of these products in the region. Additionally, higher adoption of genomics services and proteomic-based platforms in the region has led to an increase in the adoption of cloning and mutagenesis tools. Such aforementioned factors have contributed towards high market growth in the region.